Abstract: . . .  and safety of omapatri- late in subjects with isolated systolic hypertension . Ann Meeting of Internat Soc Hypertens 2000, Chicago. Vasopeptidase Inhibition 2:110-1. 28. Sagie A, Larson MG, Levy D. The natural history of borderline isolated sys- tolic hypertension . N Engl J Med 1993; 329:1912-7.  . . .
. . .  tolerability of losartan versus atenolol in patients with isolated systolic hypertension . J Hypertens 2000; 18:795-802. 27. Larochelle P, Smith DHG, Ouellet J et al. Efficacy and safety of omapatri- late in subjects with isolated systolic hypertension . Ann Meeting of Internat Soc Hypertens 2000, Chicago. Vasopeptidase Inhibition 2:110-1. 28. Sagie A, Larson MG, Levy D. The natural history of borderline isolated sys- tolic hypertension . N Engl J Med 1993; . . .
. . .  with isolated systolic hypertension . Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-64. 16. Franse LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-54. 17. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older . . .
. . .  1998;16:1823-29. 20. Brown MJ, Castaigne A, de Leeuw PW et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35:1038-42. 21. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72. 22. Kostis JB, Pressel SL, Cutler JA et al. Prevention of heart failure by antihy- pertensive . . .
. . .  al. for Losartan Investigators Group. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension . J Hypertens 2000; 18:795-802. 27. Larochelle P, Smith DHG, Ouellet J et al. Efficacy and safety of omapatri- late in subjects with isolated systolic hypertension . Ann Meeting of Internat Soc Hypertens 2000, Chicago. Vasopeptidase Inhibition 2:110-1. 28. Sagie A, Larson MG, Levy D. The natural history of borderline . . .
. . .  untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72. 22. Kostis JB, Pressel SL, Cutler JA et al. Prevention of heart failure by antihy- pertensive drug treatment in older persons with isolated systolic hyperten- sion. JAMA 1997; 278:212-6. 23. Avanzini F, Alli B, Betteli G et al. Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension . . .
--2956,6,246,3218,14778